share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

諾和諾德 | 6-K:諾和諾德-股票回購計劃
美股SEC公告 ·  06/24 12:10
Moomoo AI 已提取核心訊息
Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program. The company, headquartered in Denmark, initiated the program on May 6, 2024, as part of a larger DKK 20 billion buyback plan set to occur over a 12-month period starting February 6, 2024. As of June 24, 2024, Novo Nordisk has repurchased 1,150,040 B shares under the current program, with a total expenditure of DKK 1,082,466,722. The transactions were made between June 17 and June 21, 2024, with the number of shares purchased each day ranging from 36,000 to 36,500 at average prices between DKK 979.90 and DKK 986.99. Overall, since the beginning of the buyback period in February, the company has acquired 9,884,290 B shares at an average price of DKK 871.10 per share, amounting to a total spend of DKK 8,610,201,494. Novo Nordisk now holds 11,249,854 B shares as treasury shares, which is 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program. The company, headquartered in Denmark, initiated the program on May 6, 2024, as part of a larger DKK 20 billion buyback plan set to occur over a 12-month period starting February 6, 2024. As of June 24, 2024, Novo Nordisk has repurchased 1,150,040 B shares under the current program, with a total expenditure of DKK 1,082,466,722. The transactions were made between June 17 and June 21, 2024, with the number of shares purchased each day ranging from 36,000 to 36,500 at average prices between DKK 979.90 and DKK 986.99. Overall, since the beginning of the buyback period in February, the company has acquired 9,884,290 B shares at an average price of DKK 871.10 per share, amounting to a total spend of DKK 8,610,201,494. Novo Nordisk now holds 11,249,854 B shares as treasury shares, which is 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
領先的全球醫療保健公司諾和諾德(Novo Nordisk A/S)在分享回購計劃方面取得了進展。該公司總部位於丹麥,於2024年5月6日啓動了該計劃,作爲總額爲200億丹麥克朗的回購計劃的一部分,該計劃將在2024年2月6日開始的12個月內實施。截至2024年6月24日,諾和諾德已在當前計劃下回購了1,150,040股B股,總花費爲10,824,667,22丹麥克朗。這些交易是在2024年6月17日至6月21日之間進行的,每天購買的股數在36,000至36,500之間,平均價格介於979.90丹麥克朗至986.99丹麥克朗之間。總體而言,自2月份回購期開始以來,該公司已以平均每股871.10丹麥克朗的價格收購了9,884,290股B股,總花費爲86,102,014,94丹麥克朗。諾和諾德現持有11,249,854股B股作爲庫存股份,佔總股本的0.3%。該公司的股票在納斯達克哥本哈根上交易,其ADR在紐約證券交易所上市。
領先的全球醫療保健公司諾和諾德(Novo Nordisk A/S)在分享回購計劃方面取得了進展。該公司總部位於丹麥,於2024年5月6日啓動了該計劃,作爲總額爲200億丹麥克朗的回購計劃的一部分,該計劃將在2024年2月6日開始的12個月內實施。截至2024年6月24日,諾和諾德已在當前計劃下回購了1,150,040股B股,總花費爲10,824,667,22丹麥克朗。這些交易是在2024年6月17日至6月21日之間進行的,每天購買的股數在36,000至36,500之間,平均價格介於979.90丹麥克朗至986.99丹麥克朗之間。總體而言,自2月份回購期開始以來,該公司已以平均每股871.10丹麥克朗的價格收購了9,884,290股B股,總花費爲86,102,014,94丹麥克朗。諾和諾德現持有11,249,854股B股作爲庫存股份,佔總股本的0.3%。該公司的股票在納斯達克哥本哈根上交易,其ADR在紐約證券交易所上市。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息